Devices, digital health, and the technology changing how care is delivered.
Eli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its lead.”
Galmed Pharmaceuticals acquired Colospan in a $4.5 million million deal as the Israel-based biotech looks to create a gastrointestinal platform targeting a dx sector valued at $6 billion.
Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to increase. New IPOs and the recovery of venture capital funding are helping, as well.
Parabilis Medicines’ IPO has lived up to the hype—securing $670 million for the largest listing in the biotech sector’s history.
Novartis has stuck on a second deal with Orionis Biosciences, this time handing $40 million upfront to the molecular glue biotech to work on “challenging therapeutic targets across multiple disease areas.”
Ethyreal Bio has exited stealth with $101 million, joining the queue of companies preparing to challenge Amgen’s Tepezza.
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a $125 million series B with the backing of some of the biggest names in pharma.
Since GLP-1 drugs like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide took the world by storm for their potent treatment of diabetes and obesity, they have also been plagued by a clinical conundrum. In some studies, the peptides seem to possess antidepressant effects, while in others they’ve been linked to worse mental health and even increased suicidality.
Even as industry watchers pit the two assets against one another, it’s too early to say whose next-generation incretin stands supreme between Novo Nordisk’s CagriSema and Eli Lilly’s retatrutide, Novo’s chief scientific officer suggested to Fierce at the ADA 2026 Scientific Sessions in New Orleans this past Sunday.
When Charles River Laboratories CEO Birgit Girshick started her career as an executive assistant with the company in Germany in 1989, she didn’t know what was possible for her career in the world of biotech. She did know she wanted to make a difference.
Novo Nordisk CEO Mike Doustdar told Fierce in an interview that he always believed the Big Pharma “did actually need to become more competitive.”
Kardigan has sewn up its IPO plans, with the cardiovascular biotech expecting to bring in a cozy $320 million from its planned Nasdaq listing.
Fierce Biotech is returning to the U.K. in November for a day of curated discussions and networking at The Savoy, London’s iconic hotel.
Rigid adenoviral platforms can derail GMP progress. Learn how adaptive, adenovirus-specific strategies reduce risk from development to scale.
Predicta Biosciences, a precision oncology specialist, is teaming with the Clínica Universidad de Navarra’s CIMA Lab Diagnostics clinic to offer an assay focused on blood cancers.
Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another round of layoffs from the South San Francisco subsidiary of Roche. The departures are part of a restructuring of the Genentech Research and Early Development (gRED) group. The company did not reveal how many positions are being affected.
There was a big uptick in the use of AI across all HHS agencies in 2025, though analysts note some use cases may “reflect new reporting requirements instead of new deployments."
Roche received approval through the EU’s In Vitro diagnostic regulation for several label expansions of its companion diagnostic platform that can identify a cancer patient's mismatch repair (MMR) status.
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year strategic plan. But to CEO Naoki Okamura, “it’s not simply saving the cost or reducing the headcount.”
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies about the next steps for its dystrophy prospect.
Over-the-counter drugmaker Perrigo Company is washing its hands of chief executive Patrick Lockwood-Taylor, who resigned from his post of president and CEO after the company’s board of directors found “certain personal conduct” by Lockwood-Taylor inconsistent with its code of conduct and “core values.” Board member Albert Manzone is stepping up to replace the CEO in the interim as the board searches for a permanent successor.
Boehringer Ingelheim’s Hernexeos has nabbed a companion diagnostic from Guardant Health after the FDA cleared its liquid biopsy test, Guardant360 CDx.
Christelle Huguet, Ph.D., Ipsen’s executive vice president and head of R&D, sits down with Fierce Healthcare & Life Sciences Editor-in-Chief Ayla Ellison to discuss pipeline discipline, external partnerships and key 2026 milestones.
Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week.